Fentanyl Citrate
NDC Package 0093-7869-65

11-digit billing NDC: 00093786965 · Billing unit: EA · 30 EA per package

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Fentanyl Citrate is oral Transmucosal Fentanyl Citrate (OTFC) is indicated for the management of breakthrough pain in cancer patients 16 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. Marketed by Teva Pharmaceuticals Usa, Inc., this product is identified by NDC 0093-7869 and is authorized under FDA application NDA020747.

Identification & Billing

NDC Package Code
0093-7869-65
Package Description
30 BLISTER PACK in 1 CARTON / 1 LOZENGE in 1 BLISTER PACK (0093-7869-19)
Product Code
11-Digit Billing Format
00093786965
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA

Clinical Specifications

Proprietary Name
Fentanyl Citrate
Dosage Form
-
Usage Information
Oral Transmucosal Fentanyl Citrate (OTFC) is indicated for the management of breakthrough pain in cancer patients 16 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking, for one week or longer, around-the-clock medicine consisting of at least 60 mg of oral morphine per day, at least 25 mcg of transdermal fentanyl per hour, at least 30 mg of oral oxycodone per day, at least 8 mg of oral hydromorphone per day, at least 25 mg oral oxymorphone per day, at least 60 mg of oral hydrocodone per day, or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids when taking OTFC. Limitations of Use:•Not for use in opioid non-tolerant patients.•Not for use in the management of acute or postoperative pain, including headache/migraine and dental pain [see Contraindications (4)].•As a part of the TIRF REMS Access program, OTFC may be dispensed only to outpatients enrolled in the program [see Warnings and Precautions (5.7)]. For inpatient administration of OTFC (e.g., hospitals, hospices, and long-term care facilities that prescribe for inpatient use), patient and prescriber enrollment is not required.

Regulatory & Marketing

Labeler Name
Teva Pharmaceuticals Usa, Inc.
FDA Application #
NDA020747
Marketing Category
NDA AUTHORIZED GENERIC - A product marketed as a "generic" drug under an approved New Drug Application (NDA), rather than an Abbreviated New Drug Application (ANDA),.
Start Marketing Date
12-08-2015
End Marketing Date
10-31-2025
Listing Expiration
10-31-2025
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0093-7869-65 identifies a specific commercial package of 30 blister pack in 1 carton / 1 lozenge in 1 blister pack (0093-7869-19) of Fentanyl Citrate, labeled by Teva Pharmaceuticals Usa, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Teva Pharmaceuticals Usa, Inc. on December 08, 2015. The current certification is valid through October 31, 2025.

How is this Teva Pharmaceuticals Usa, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00093786965. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0093-7869-65
11-Digit CMS (5-4-2)
00093-7869-65

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.